Ep. 75 - "Professionals": Dr. Michael Canney, Chief Scientific Officer at Carthera - Cutting edge ultrasound technology for Gliobalstoma treatment
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Ep. 75 - "Professionals": Dr. Michael Canney, Chief Scientific Officer at Carthera - Cutting edge ultrasound technology for Gliobalstoma treatment
-
Narrated by:
-
By:
About this listen
This week on the Let’s Talk F*ng Cancer podcast, we’re diving headfirst into the future of brain cancer treatment with none other than Dr. Michael Canney, Chief Scientific Officer at Carthera — the minds behind the groundbreaking SonoCloud-9®. 🧠⚡
Carthera is revolutionizing how we fight glioblastoma, one of the most aggressive brain cancers out there. With their implantable ultrasound device that opens the blood-brain barrier, they’re giving chemo a chance to actually work — and giving patients a fighting shot. 🙌💊
This isn’t just innovation. It’s a f*ng game-changer.
👂 Tune in to hear how Dr. Canney and the Carthera team are pushing science forward and giving new hope to those battling GBM.
🎧 Available now wherever you get your podcasts!
#LetsTalkFuckingCancer #Glioblastoma #BrainCancer #Carthera #SonoCloud9 #DrMichaelCanney #CancerPodcast #GBM #BreakthroughScience #MedicalInnovation #FuckCancer
Sonobird Clinical Trial
Carthera Advanced Brain Therapy
NeuroNews: Carthera 2023
NeuroNews: Carthera 2024
Biospace: Milestone in SONOBIRD pivotal trial April 2025
Medical Design and Development: Trial begins April 2025